CY1123735T1 - Φαρμακευτικη χρηση toy fam19a5 που εμπλεκεται στη ρυθμιση γλοιογενησης - Google Patents
Φαρμακευτικη χρηση toy fam19a5 που εμπλεκεται στη ρυθμιση γλοιογενησηςInfo
- Publication number
- CY1123735T1 CY1123735T1 CY20201101116T CY201101116T CY1123735T1 CY 1123735 T1 CY1123735 T1 CY 1123735T1 CY 20201101116 T CY20201101116 T CY 20201101116T CY 201101116 T CY201101116 T CY 201101116T CY 1123735 T1 CY1123735 T1 CY 1123735T1
- Authority
- CY
- Cyprus
- Prior art keywords
- fam19a5
- gliogenesis
- involved
- regulation
- pharmaceutical use
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
Abstract
Η παρούσα εφεύρεση αφορά στη φαρμακευτική χρήση του FAM19A5 που εμπλέκεται στη ρύθμιση της γλοιογένεσης, και πιο συγκεκριμένα, στη χρήση του FAM19Α5 στην πρόληψη, διάγνωση ή θεραπεία βλαβών του κεντρικού νευρικού συστήματος, εκφυλιστικών εγκεφαλικών ασθενειών ή ασθενειών του κεντρικού νευρικού συστήματος, με το FAM19A5 εξαπλώνεται στα νευρικά βλαστοκύτταρα στα σπονδυλωτά και να ρυθμίζει τη γλοιογένεση.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20120015177 | 2012-02-15 | ||
PCT/KR2013/001179 WO2013122408A1 (ko) | 2012-02-15 | 2013-02-15 | 신경교세포 생성 조절에 관여하는 fam19a5의 약제학적 용도 |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1123735T1 true CY1123735T1 (el) | 2022-03-24 |
Family
ID=49218126
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20201101116T CY1123735T1 (el) | 2012-02-15 | 2020-11-25 | Φαρμακευτικη χρηση toy fam19a5 που εμπλεκεται στη ρυθμιση γλοιογενησης |
Country Status (12)
Country | Link |
---|---|
US (4) | US9579398B2 (el) |
EP (2) | EP3827848A1 (el) |
KR (1) | KR101406393B1 (el) |
CN (2) | CN104254343A (el) |
CY (1) | CY1123735T1 (el) |
DK (1) | DK2815769T3 (el) |
ES (1) | ES2838814T3 (el) |
HU (1) | HUE052286T2 (el) |
LT (1) | LT2815769T (el) |
PL (1) | PL2815769T3 (el) |
PT (1) | PT2815769T (el) |
WO (1) | WO2013122408A1 (el) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013122408A1 (ko) | 2012-02-15 | 2013-08-22 | 고려대학교 산학협력단 | 신경교세포 생성 조절에 관여하는 fam19a5의 약제학적 용도 |
WO2014200030A1 (ja) * | 2013-06-12 | 2014-12-18 | 国立大学法人京都大学 | 人工多能性幹細胞の選別方法および血球への分化誘導方法 |
KR101649175B1 (ko) * | 2014-03-18 | 2016-08-22 | 충남대학교산학협력단 | 신규 samdori2 유전자 및 이의 용도 |
JP7045724B2 (ja) * | 2016-11-07 | 2022-04-01 | ニューラクル サイエンス カンパニー リミテッド | 配列類似性を持つ抗ファミリー19、メンバーa5抗体及びその用途 |
US11560425B2 (en) * | 2017-06-27 | 2023-01-24 | Neuracle Science Co., Ltd. | Use of anti-FAM19A5 antibodies for treating cancers |
JP7034499B2 (ja) * | 2017-06-27 | 2022-03-14 | ニューラクル サイエンス カンパニー リミテッド | 線維症の治療のための抗fam19a5抗体の用途 |
KR102472683B1 (ko) * | 2017-06-27 | 2022-12-01 | 주식회사 뉴라클사이언스 | 녹내장의 치료를 위한 항-서열 유사성 19를 가진 패밀리, 멤버 a5 항체의 용도 |
EP3645563A4 (en) * | 2017-06-27 | 2021-03-17 | Neuracle Science Co., Ltd | ANTI-FAM19A5 ANTIBODIES AND THEIR USES |
WO2019069229A1 (en) * | 2017-10-02 | 2019-04-11 | Neuracle Science Co., Ltd. | USE OF ANTIBODIES DIRECTED AGAINST A SIMILARITY FAMILY OF SEQUENCE 19, ELEMENT A5, FOR THE TREATMENT AND DIAGNOSIS OF MOOD DISORDERS |
CN110386973B (zh) * | 2018-04-18 | 2022-09-27 | 北京大学 | 具有多种功能的蛋白多肽及其医药用途 |
CN112424223A (zh) * | 2018-04-24 | 2021-02-26 | 纽洛可科学有限公司 | 抗序列相似家族19成员a5的抗体在治疗神经性疼痛中的用途 |
AU2019265855A1 (en) * | 2018-05-08 | 2020-11-26 | Neuracle Genetics | Adeno-associated virus (AAV) delivery of anti-FAM19A5 antibodies |
KR102661891B1 (ko) * | 2018-05-10 | 2024-05-23 | 주식회사 뉴라클사이언스 | 서열 유사성 19, 멤버 a5 항체를 갖는 항-패밀리 및 그의 사용 방법 |
US20210347872A1 (en) * | 2018-10-16 | 2021-11-11 | Neuracle Science Co., Ltd. | Use of anti-fam19a5 antibodies |
CN113227139A (zh) * | 2018-12-27 | 2021-08-06 | 纽洛可科学有限公司 | 抗fam19a5抗体治疗动脉粥样硬化的用途 |
EP3906260A4 (en) * | 2019-01-02 | 2022-08-31 | Neuracle Science Co., Ltd | SEQUENCE-LIKE ANTI-FAMILY ANTIBODIES 19, MEMBER A5 AND METHOD OF USE THEREOF |
KR102328773B1 (ko) * | 2019-04-23 | 2021-11-19 | 고려대학교 산학협력단 | Fam19a5l 유전자를 녹아웃 시킨 제브라피쉬 동물모델 및 이의 제조방법 |
US20230104540A1 (en) * | 2020-03-02 | 2023-04-06 | Neuracle Science Co., Ltd. | Use of anti-fam19a1 antagonists for treating central nervous system diseases |
CN113491764B (zh) * | 2020-04-03 | 2023-09-19 | 北京大学 | Fam19a5的医药用途 |
IL310026A (en) * | 2021-07-08 | 2024-03-01 | Neuracle Science Co Ltd | Inhibitors and methods of using them |
EP4367128A1 (en) * | 2021-07-08 | 2024-05-15 | Neuracle Science Co., Ltd. | Polypeptide inhibitors and uses thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3217372A1 (de) | 1982-05-08 | 1983-11-10 | Bayer Ag, 5090 Leverkusen | Sulfonsaeureamidamine, ihre herstellung und verwendung |
SE9804064D0 (sv) * | 1998-11-25 | 1998-11-25 | A & Science Invest Ab | Medicinal product and method for treatment of conditions affecting neural stem cells or progenitor cells |
EP2287340A3 (en) * | 2005-05-11 | 2011-03-30 | Aarhus Universitet | Method for diagnosis and treatment of a mental disease |
US8470295B2 (en) * | 2007-05-10 | 2013-06-25 | Peak Biosciences, Inc. | Methods of treatment of androgenic steroidal hormone dependent cancer with auger electron-emitting nucleoside analogs |
US20110076256A1 (en) | 2008-08-12 | 2011-03-31 | Industry-Academic Cooperation Foundation, Yonsei University | Human Neural Stem Cell and Pharmaceutical Composition for the Treatment of Central or Peripheral Nervous System Disorders or Injuries Using Same |
CN102775490B (zh) * | 2011-05-12 | 2017-04-12 | 北京大学 | 具有趋化活性的分泌蛋白及其应用 |
WO2013122408A1 (ko) | 2012-02-15 | 2013-08-22 | 고려대학교 산학협력단 | 신경교세포 생성 조절에 관여하는 fam19a5의 약제학적 용도 |
-
2013
- 2013-02-15 WO PCT/KR2013/001179 patent/WO2013122408A1/ko active Application Filing
- 2013-02-15 PT PT137487914T patent/PT2815769T/pt unknown
- 2013-02-15 PL PL13748791T patent/PL2815769T3/pl unknown
- 2013-02-15 EP EP20202800.7A patent/EP3827848A1/en active Pending
- 2013-02-15 DK DK13748791.4T patent/DK2815769T3/da active
- 2013-02-15 CN CN201380011868.5A patent/CN104254343A/zh active Pending
- 2013-02-15 CN CN201710128488.XA patent/CN107019800A/zh active Pending
- 2013-02-15 HU HUE13748791A patent/HUE052286T2/hu unknown
- 2013-02-15 EP EP13748791.4A patent/EP2815769B1/en active Active
- 2013-02-15 LT LTEP13748791.4T patent/LT2815769T/lt unknown
- 2013-02-15 ES ES13748791T patent/ES2838814T3/es active Active
- 2013-02-15 US US14/378,505 patent/US9579398B2/en active Active
- 2013-02-15 KR KR20130016094A patent/KR101406393B1/ko active IP Right Grant
-
2017
- 2017-01-11 US US15/404,011 patent/US10640557B2/en active Active
-
2020
- 2020-03-03 US US16/807,902 patent/US11739141B2/en active Active
- 2020-11-25 CY CY20201101116T patent/CY1123735T1/el unknown
-
2023
- 2023-07-11 US US18/350,287 patent/US20240166735A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20240166735A1 (en) | 2024-05-23 |
US20200270337A1 (en) | 2020-08-27 |
WO2013122408A1 (ko) | 2013-08-22 |
LT2815769T (lt) | 2020-11-25 |
US20170121401A1 (en) | 2017-05-04 |
US20150118230A1 (en) | 2015-04-30 |
CN104254343A (zh) | 2014-12-31 |
CN107019800A (zh) | 2017-08-08 |
PT2815769T (pt) | 2020-12-07 |
US11739141B2 (en) | 2023-08-29 |
DK2815769T3 (da) | 2020-12-14 |
EP2815769A4 (en) | 2015-08-19 |
US9579398B2 (en) | 2017-02-28 |
EP3827848A1 (en) | 2021-06-02 |
PL2815769T3 (pl) | 2021-05-04 |
HUE052286T2 (hu) | 2021-04-28 |
KR20130094255A (ko) | 2013-08-23 |
KR101406393B1 (ko) | 2014-06-13 |
ES2838814T3 (es) | 2021-07-02 |
EP2815769A1 (en) | 2014-12-24 |
US10640557B2 (en) | 2020-05-05 |
EP2815769B1 (en) | 2020-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1123735T1 (el) | Φαρμακευτικη χρηση toy fam19a5 που εμπλεκεται στη ρυθμιση γλοιογενησης | |
CY1124729T1 (el) | Φαρμακοτεχνικες μορφες του ενζαλουταμιδιου | |
CY1124311T1 (el) | Παρεμποδιστες dna-pk | |
CY1121826T1 (el) | Προφαρμακα καρβιντοπας και l-ντοπας και η χρηση τους στην αγωγη της νοσου parkinson | |
CY1120390T1 (el) | Συνθεση και μεθοδος για διαγνωση και θεραπεια ασθενειων που σχετιζονται με εκφυλισμο νευριτων | |
MX2021007268A (es) | Formas solidas de acido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acetico, composiciones, y usos de las mismas. | |
MX2017013562A (es) | Reguladores de microbioma y usos relacionados de los mismos. | |
CY1121097T1 (el) | Ανθρωπινα αντισωματα κατα toy gfr 3 και μεθοδοι χρησης αυτων | |
BR112017024384A2 (pt) | bactérias modificadas para reduzir hiperfenilalaninemia | |
BR112015010663A8 (pt) | formas de dosagem oral de liberação sustentada, e uso de ruxolitinib ou de sal farmaceuticamente aceitável do mesmo | |
CL2016001895A1 (es) | Compuestos | |
ECSP13012648A (es) | Inmunoglobulinas con dominio variable dual y usos de las mismas | |
DOP2013000047A (es) | Inmunoglobulinas con dominio variable dual y usos de las mismas | |
EA201790273A1 (ru) | Флагеллиновые композиции и их применение | |
ECSP14008556A (es) | Pirimidinas y triazinas fusionadas sustituidas y su uso | |
DOP2013000025A (es) | Inmunoglobulinas con dominio variable dual y usos de las mismas | |
JO3343B1 (ar) | أحماض 5- أمينوتتراهيدروكوينولين-2- كربوكسيليك جديدة واستخدامها | |
ECSP13012824A (es) | Derivados de (1,2,4)triazolo[4,3-a)quinoxalina como inhibidores de fosfodiesterasas | |
EA201992707A1 (ru) | Соединения и их применения для модуляции гемоглобина | |
WO2014151456A3 (en) | Treatment of inflammatory diseases | |
CO7350653A2 (es) | Retinoides y uso de los mismos | |
CL2015003563A1 (es) | Marcador para trastornos de la esfingomielinasa ácida y sus usos. | |
TR201905218T4 (tr) | Nörodejenerati̇f hastaliklarin tedavi̇si̇ i̇çi̇n yararli vi̇tanoli̇dler. | |
EA201500232A1 (ru) | Три(гетеро)арилпиразолы и их применение | |
ECSP13012523A (es) | Inmunoglobulinas con dominio variable dual y usos de las mismas |